Notably, Tworoger et al. showed evidence from elegant studies indicating that higher levels of plasma prolactin were associated with an increased risk of breast cancer in both premenopausal and postmenopausal women, which was especially prominent for the estrogen receptor+/progesterone receptor+ cancer type8, 9. This evidence concerns the gene ESR1 and breast carcinoma.